Mucopolysaccharidosis type I (MPS I) is an inherited lysosomal disorder caused by pathogenic variants in the IDUA gene. It is transmitted in an autosomal recessive pattern and is due to the deficiency of the enzyme alpha-L-iduronidase, which is necessary for the degradation of the glycosaminoglycans dermatan sulfate and heparan sulfate. Its progressive accumulation in lysosomes causes multisystem involvement, especially skeletal, cardiac, respiratory, ocular, and neurological.
Mucopolysaccharidosis type 1
The IDUA gene encodes the enzyme alpha-L-iduronidase, a lysosomal hydrolase responsible for removing alpha-L-iduronic acid residues during the degradation of glycosaminoglycans (GAGs), primarily dermatan sulfate and heparan sulfate. These compounds are part of the extracellular matrix and must be continuously recycled. When IDUA activity is reduced or absent, GAGs are not degraded properly and accumulate within lysosomes, altering cell function and the normal development of multiple tissues.
MPS I constitutes a continuous clinical spectrum that has traditionally been divided into Hurler, Hurler-Scheie, and Scheie syndromes, although it is currently usually classified into severe and attenuated forms. Severe forms present with progressive neurological involvement, while attenuated forms usually preserve cognitive function but can present with significant osteoarticular, cardiac, respiratory, and ocular disease. The disease is inherited in an autosomal recessive manner; affected individuals inherit two pathogenic variants in IDUA, one from each parent. Its global incidence is estimated at around 1 in 100,000 live births, with variations between populations.
Symptoms
The age of onset and severity depend on the phenotype. The severe form usually manifests during the first year of life with coarse facial features, recurrent respiratory infections, hernias, hepatosplenomegaly, multiple dysostoses, joint stiffness, corneal clouding, and developmental delay. With progression, hydrocephalus, hearing loss, valvular heart disease, and neurological deterioration may appear. Milder forms usually begin later, in childhood or adolescence, with joint involvement, short stature, respiratory problems, corneal clouding, and heart disease, generally without significant cognitive impairment.
Disease management
Management requires multidisciplinary follow-up and specific treatment when indicated. Enzyme replacement therapy with intravenous laronidase may improve somatic manifestations such as hepatosplenomegaly, exercise intolerance, and respiratory function, although its central nervous system penetration is limited. In the severe form, early hematopoietic stem cell transplantation is the treatment of choice to attempt to preserve neurological function and improve survival. In addition, cardiological, respiratory, ophthalmological, auditory, and orthopedic monitoring is necessary, as well as management of infections, sleep apnea, pain, and functional limitation.
Genes analyzed
Bibliography
Clarke LA. Mucopolysaccharidosis Type I. 2002 Oct 31 [updated 2025 Dec 4]. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025.
Poletto E, Pasqualim G, Giugliani R, et al. Worldwide distribution of common IDUA pathogenic variants. Clin Genet. 2018 Jul;94(1):95-102.
Gul R, Firasat S, Hussain M, et al. IDUA gene mutations in mucopolysaccharidosis type-1 patients from two Pakistani inbred families. Congenit Anom (Kyoto). 2020 Jul;60(4):126-127.
Zahoor MY, Cheema HA, Ijaz S, et al. Mapping of IDUA gene variants in Pakistani patients with mucopolysaccharidosis type 1. J Pediatr Endocrinol Metab. 2019 Nov 26;32(11):1221-1227.
